Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Rotschafer

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The Annals of Pharmacotherapy|October 8, 2009
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patientsJohn C Rotschafer, Mary Ullman
Pharmacotherapy|January 30, 2015
Polymyxins in 2015: it's like déjà vu all over againJason M Pogue, John C Rotschafer
Infectious Disease Clinics of North America|January 9, 2004
Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applicationsElizabeth D Hermsen, Christopher J Sullivan, John C Rotschafer
Antimicrobial Agents and Chemotherapy|October 3, 2007
In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysateFrances L Clouse, Laurie B Hovde, John C Rotschafer
The American Journal of Medicine|July 5, 2005
Antimicrobial treatment of lower respiratory tract infections in the hospital settingRonald F Grossman, John C Rotschafer, James S Tan
Diagnostic Microbiology and Infectious Disease|December 7, 2007
Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposureLaurie B Hovde, Dana A Simonson, John C Rotschafer
Diagnostic Microbiology and Infectious Disease|February 13, 2007
Adverse events associated with the use of oral cephalosporins/cephemsIsaac F Mitropoulos, John C Rotschafer, Keith A Rodvold
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM)Jeremy A Schafer, Laurie B Hovde, John C Rotschafer
Critical Care Clinics|December 15, 2010
Optimal use of fluoroquinolones in the intensive care unit settingJohn C Rotschafer, Mary A Ullman, Christopher J Sullivan
Pharmacotherapy|December 5, 2013
Vancomycin: over 50 years later and still a work in progressMichael J Rybak, John C Rotschafer, Keith A Rodvold
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The Annals of Pharmacotherapy|October 8, 2009
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patientsJohn C Rotschafer, Mary Ullman
Pharmacotherapy|January 30, 2015
Polymyxins in 2015: it's like déjà vu all over againJason M Pogue, John C Rotschafer
Infectious Disease Clinics of North America|January 9, 2004
Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applicationsElizabeth D Hermsen, Christopher J Sullivan, John C Rotschafer
Antimicrobial Agents and Chemotherapy|October 3, 2007
In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysateFrances L Clouse, Laurie B Hovde, John C Rotschafer
The American Journal of Medicine|July 5, 2005
Antimicrobial treatment of lower respiratory tract infections in the hospital settingRonald F Grossman, John C Rotschafer, James S Tan
Diagnostic Microbiology and Infectious Disease|December 7, 2007
Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposureLaurie B Hovde, Dana A Simonson, John C Rotschafer
Diagnostic Microbiology and Infectious Disease|February 13, 2007
Adverse events associated with the use of oral cephalosporins/cephemsIsaac F Mitropoulos, John C Rotschafer, Keith A Rodvold
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM)Jeremy A Schafer, Laurie B Hovde, John C Rotschafer
Critical Care Clinics|December 15, 2010
Optimal use of fluoroquinolones in the intensive care unit settingJohn C Rotschafer, Mary A Ullman, Christopher J Sullivan
Pharmacotherapy|December 5, 2013
Vancomycin: over 50 years later and still a work in progressMichael J Rybak, John C Rotschafer, Keith A Rodvold
Pageof 4